GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Institutional Ownership

Aravive (STU:VE11) Institutional Ownership : 2.89% (As of Jun. 28, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Aravive Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aravive's institutional ownership is 2.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aravive's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aravive's Float Percentage Of Total Shares Outstanding is 61.57%.


Aravive Institutional Ownership Historical Data

The historical data trend for Aravive's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Institutional Ownership Chart

Aravive Historical Data

The historical data trend for Aravive can be seen below:

2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31
Institutional Ownership 12.12 12.13 10.84 9.26 7.82 6.34 6.12 2.96 2.96 2.89

Aravive Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Aravive Business Description

Traded in Other Exchanges
N/A
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive Headlines

No Headlines